TEXAS, October 23, 2025: Scientists at the Texas A&M University Health Science Center have identified a hidden cellular mechanism that fuels one of the most aggressive forms of kidney cancer affecting children and young adults. The discovery, published in Nature Communications, reveals how cancer cells exploit RNA molecules to promote tumor growth and describes a molecular method capable of halting the process in preclinical models.
The research centers on translocation renal cell carcinoma (tRCC), a rare cancer that accounts for roughly 30 percent of kidney cancers in pediatric and adolescent patients. This malignancy arises from chromosomal rearrangements that create hybrid genes known as TFE3 oncofusions. These fusion genes alter normal cellular function and trigger uncontrolled growth, contributing to the tumor’s rapid progression and resistance to conventional therapies.
According to the study, RNA molecules, which normally serve as messengers carrying genetic information, are repurposed by cancer cells to form liquid-like structures called “droplet hubs” within the nucleus. These hubs act as centers of activity that activate growth-promoting genes. The researchers found that the TFE3 fusion proteins interact with an RNA-binding protein known as PSPC1 to stabilize these droplets, enhancing their ability to drive tumor development.
The team employed advanced molecular biology tools, including CRISPR gene editing and next-generation sequencing, to map the interactions between RNA, TFE3 fusion proteins, and other cellular components. Their work showed that these interactions facilitate the assembly of transcriptional machinery within the droplet hubs, which in turn amplifies the expression of oncogenic genes.
Chemogenetic tool halts tumor spread in preclinical studies
To counter this process, the researchers developed a nanobody-based chemogenetic switch that can dissolve the RNA-protein droplets when activated. In both laboratory cell cultures and animal models, activating this switch disrupted the formation of the condensates, effectively stopping tumor growth. The ability to disassemble these structures without damaging surrounding cells marks a significant step forward in understanding how certain cancers can be precisely targeted at their molecular source.
Dr. Yun Huang, professor at the Institute of Biosciences and Technology at Texas A&M, said the study demonstrates that RNA acts not only as a messenger but also as a key structural component in tumor biology. Dr. Yubin Zhou, director of the Center for Translational Cancer Research, emphasized that the discovery could guide the development of treatments that specifically target these molecular condensates, offering a more refined approach than existing broad-spectrum therapies.
The research team noted that the findings could have implications for other cancers driven by fusion genes similar to TFE3 oncofusions, which are often seen in pediatric tumors. By identifying how RNA and fusion proteins cooperate to create these droplet hubs, scientists can pinpoint molecular vulnerabilities that may be exploited for future therapeutic development.
Laboratory models confirm halted tumor progression
Translocation renal cell carcinoma remains one of the most challenging forms of kidney cancer to treat due to its rarity and lack of targeted therapies. Current treatment options are largely limited to surgery and general chemotherapy, which often yield limited success. The Texas A&M team’s work provides a foundation for potential new treatment strategies grounded in precise molecular disruption rather than broad cellular targeting.
The study underscores a growing area of research into how liquid-like condensates within cells influence gene regulation and cancer development. By defining how these structures form and can be dismantled, scientists are gaining critical insight into previously hidden drivers of malignancy that could inform the next generation of cancer treatments. – By Content Syndication Services.